Authors: M. Gazouli, N. Nikiteas, NP. Anagnou, N. Kelekis, E. Efstathopoulos
Affilation: School of Medicine University of Athens, Greece
Pages: 396 - 398
Keywords: colorectal cancer, ck19, nanoprobes, quantum dots
The aim of the study was to develop and validate a QD-nanoprobe for the detection of CK19 protein for in vivo colorectal cancer molecular targeting. QDs with a maximum emission wavelength of 655 nm, were coated with streptavidin and functionalized with the biotinylated-CK19-antibody. In vitro binding affinity of these nanoprobes was evaluated in a panel of cell lines and clinical samples. For in vivo experiments, male NOD/SCID mice were used. Animals were injected with DLD-1 colorectal cancer cell. Upon reaching a tumor size of approximately 0.8 to 1 cm, were administered an into the tail vein injection of 10 pmol QD nanoparticles and CK19-QD nanoprobes and imaged at various time points. In vivo optical imaging was done using the IVIS imaging system 50 series. CK19-QD showed CK19-specific binding in vitro. Animals were euthanized after the injection of QD and CK19-QD. At the 3h time point, CK19-QD nanoprobes showed more prominent fluorescence when compared with QD nanoparticles. At 24h, both QD and CK19-QD fluorescence decreased to near-baseline levels. CK19-QD probes have good optical properties and biocompatibility for in vivo targeted imaging of colorectal cancer. Such approach promises to be highly desirable for molecular targeted research of gastrointestinal cancer.
Nanotech Conference Proceedings are now published in the TechConnect Briefs